On September 17, 2021 Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, reported that it has signed a license agreement with the Swiss-based FarmaMondo Group for the commercialization of Paclical (Apealea) in Russia and the Commonwealth of Independent States (Press release, Oasmia, SEP 17, 2021, View Source [SID1234587943]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization and is used for the treatment of for epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer.
Under the terms of the agreement, the marketing authorizations which Oasmia holds in Russia and Kazakhstan will be transferred to FarmaMondo. FarmaMondo will also be responsible for all future development and commercialization activities in Russia and the Commonwealth of Independent States, which includes Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan. Oasmia will supply FarmaMondo with Paclical and will receive product supply revenues.
The signing of this agreement heralds the completion of the out-licensing of Apealea globally and Oasmia anticipates starting to receive royalties from these partnerships during 2022.
François Martelet, M.D., CEO of Oasmia, commented: "FarmaMondo is an excellent commercial partner for Paclical with a rapidly growing portfolio of high quality products in Russia and the CIS. It is focused on providing market access and specialty distribution services, through its unique and established infrastructure and geographical footprint. This agreement will enable us to focus our resources on significant value-enhancing corporate activities including pipeline development and M&A."
Yaron Spigel, President of the Board and Group CEO at FarmaMondo added: "We are looking forward to commercialising and selling Paclical in Russia and the CIS. Cremophor-EL is highly toxic, requires long infusion times, and can cause serious hypersensitive allergic reactions, requiring premedication with steroids and antihistamines. As a non-Cremophor based formulation of paclitaxel we believe that Paclical could offer a valuable alternative for many advanced ovarian cancer patients."